Horizon Pharma plc Announces the Launch of “Cystinosis United” to Educate, Inspire and Connect the Cystinosis Community
30 janv. 2018 08h30 HE
|
Horizon Pharma plc
DUBLIN, Ireland, Jan. 30, 2018 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP) today announced the launch of Cystinosis United, an initiative created for people living with nephropathic...
Horizon Pharma plc Announces FDA Approval to Expand the Indication for PROCYSBI® (cysteamine bitartrate) Delayed-Release Capsules to Include Children One Year of Age and Older Living with Nephropathic Cystinosis
27 déc. 2017 08h00 HE
|
Horizon Pharma plc
DUBLIN, Ireland, Dec. 27, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP) today announced the U.S. Food and Drug Administration (FDA) has approved an expansion to the indication for...
Horizon Pharma plc Announces Availability of PROCYSBI™ (cysteamine bitartrate) in Canada
26 oct. 2017 08h00 HE
|
Horizon Pharma plc
DUBLIN, Ireland, Oct. 26, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and...
Horizon Pharma plc Announces Four Poster Presentations on PROCYSBI® (Cysteamine Bitartrate) Delayed-Release Capsules at Cystinosis Research Network 2017 Family Conference
14 juil. 2017 08h00 HE
|
Horizon Pharma plc
DUBLIN, Ireland, July 14, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and...
Horizon Pharma plc Announces Health Canada Approval of PROCYSBI™ (Cysteamine Delayed-Release Capsules) for the Treatment of Nephropathic Cystinosis
19 juin 2017 08h00 HE
|
Horizon Pharma plc
DUBLIN, Ireland, June 19, 2017 (GLOBE NEWSWIRE) -- Horizon Pharma plc (NASDAQ:HZNP), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and...
Raptor Pharmaceutical Corp. Reports First Quarter 2016 Financial Results
05 mai 2016 16h05 HE
|
Raptor Pharmaceutical Inc
PROCYSBI® Global Net Revenue Increased 34% Year-Over-Year, to $27.5 Million 2016 Non-GAAP Operating Expense Guidance Lowered to $125 – $135 Million Full-Year 2016 Revenue Guidance Maintained...
Raptor Pharmaceutical Launches QUINSAIR™ in Europe
11 avr. 2016 07h05 HE
|
Raptor Pharmaceutical Inc
NOVATO, Calif., April 11, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced its first commercial sale of QUINSAIR™ (levofloxacin inhalation solution) in Germany and...
Raptor Pharmaceutical to Participate in the Leerink Partners 5th Global Healthcare Conference
08 févr. 2016 07h30 HE
|
Raptor Pharmaceutical Inc
NOVATO, Calif., Feb. 08, 2016 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. (Nasdaq:RPTP) today announced that it will participate in the following investor conference: Julie Anne Smith,...
Raptor Pharmaceutical Corp. Reports Third Quarter 2015 Financial Results and Provides Corporate Update
05 nov. 2015 16h04 HE
|
Raptor Pharmaceutical Inc
Record PROCYSBI® Product Sales of $25.8 Million
Raptor Raises 2015 PROCYSBI Revenue Guidance to $90-$95 Million
Company to Host Conference Call and Webcast Today at 4:30 p.m. EST
NOVATO,...
Raptor Pharmaceutical Corp. Expands Rare Disease Portfolio With the Acquisition of Quinsair(TM)
20 août 2015 17h16 HE
|
Raptor Pharmaceutical Inc
First Inhaled Fluoroquinolone Therapy for Patients with Cystic Fibrosis
Approval Received in the European Union and Canada
Expansion of Pipeline with Multiple Late-Stage Orphan Indication...